Gain detailed insights into the trading activity of Congress members for FTAI Infrastructure on our government trades page. Stay updated on how elected officials are investing in FIP.

FTAI Infrastructure - Government Trades

FTAI Infrastructure

FTAI Infrastructure Inc is engaged in five segments; Railroad segment includes five freight railroads and one switching company that provide rail service to certain manufacturing and production facilities, the Jefferson Terminal segment consists of a multi-modal crude oil and refined products terminal and other related assets. Repauno segment consists of a 1,630-acre deep-water port located along the Delaware River with an underground storage cavern, a new multipurpose dock, a rail-to-ship transloading system, and multiple industrial development opportunities. Power and Gas segment is comprised of an equity method investment in Long Ridge, and Sustainability and Energy Transition segment is comprised of Aleon/Gladieux, Clean Planet, and CarbonFree.

movers image

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AEHR

ARDT

BLCO

CGBS

EMBC

Aehr Test Systems Posts Weak Results, Joins Trump Media &amp; Technology Group And Other Big Stocks Moving Lower In Tuesday&#39;s Pre-Market Session

ATCH

ATPC

AVGR

CANG

CHCI

HCWC

LIDR

NMHI

PHIO

PIII

RGNX

RIME

SANG

STAF

URGN

YOSH

Why KB Home Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket

Penny Stocks

Short Ideas

Small Cap

NEOV

As of April 15, 2024, three stocks in the industrials sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Top 3 Industrials Stocks That May Fall Off A Cliff In Q2

ADMP

AIRT

ALLO

AMEH

AMPX

ANPC

ATHX

BBLG

BCAN

CDRO

CELU

CPTN

DSGN

EVAX

FENC

FOXO

FREY

FRGE

GROV

HLGN

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

ICPT

IDAI

IDBA

IMTE

IRTC

KXIN

MEDS

MGAM

MOHO

MRVI

MSGM

NRBO

PBTS

PGEN

PHUN

PIXY

PLRX

PRTC

QTEK

SESN

SHPH

SLNG

SMIT

SMRT

SOBR

STIX

STKH

STRY

SVRE

TCOM

TCRT

TNDM

VEEE

VERU

VTAQ

WBEV

WKEY

XPEV

YGMZ

ZLAB

Why Stabilis Solutions Shares Jumped Over 71%; Here Are 70 Biggest Movers From Yesterday

Intraday Update

AGRI

BYND

PHAS

RMED

Why Adamis Pharmaceuticals Is Trading Lower By Around 44%, Here Are 46 Stocks Moving In Wednesday&#39;s Mid-Day Session

Earnings

Eurozone

Commodities

Global

U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 100 points on Wednesday.

S&amp;P 500 Rises 0.5%; Crude Oil Falls Sharply

DRIO

NOVA

U.S. stocks traded higher this morning, with the Dow Jones gaining around 175 points on Wednesday. The Federal Reserve will announce its policy decision at 2:00 p.m. ET. The country’s central bank is widely expected to raise interest rates by 75 bps at the meeting. Fed Chairman Jerome Powell will hold a press conference at 2:30 p.m. ET.

US Stocks Open Higher Ahead Of Fed Decision, Dow Jumps 175 Points

Long Ideas

Insider Trades

U.S. crude oil futures traded lower this morning on Thursday. Investors, meanwhile, focused on some notable insider trades.

When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Around $1.4 Million Bet On This Energy Stock? Check Out These 3 Penny Stocks Insiders Are Buying

FTAI Infrastructure Inc

Jefferies analyst Rob Dickerson maintains WK Kellogg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLG#NYSE">KLG</a>) with a Hold and lowers the price target from $19 to $16.

Price Target

Analyst Ratings

Jefferies Maintains Hold on WK Kellogg, Lowers Price Target to $16

The Food and Drug Administration on Tuesday approved Ozempic, the weight loss drug made by Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), for the treatment of chronic kidney disease in patients who also <a href="https://www.benzinga.com/25/01/42875977/novo-nordisk-seeks-to-strengthen-its-obesity-pipeline-with-back-to-back-two-biobuck-deals">have type 2 diabetes. </a>
The Details: According to the Centers for Disease Control and Prevention, more than 35.5 million Americans have chronic kidney disease, often as a complication of type 2 diabetes. The new FDA approval allows for further expansion of Ozempic's use and potential coverage by health insurance plans.&nbsp;
Read Next:<a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/43254018/sofi-stock-falls-on-soft-guidance-despite-strong-quarter-with-record-member-growth-loan-originations-analyst"> SoFi Stock Falls On Soft Guidance Despite &#8216;Strong Quarter&#8217; With Record Member Growth, Loan Originations: Analyst&nbsp;</a>
The FDA approval "allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of adults and could have serious consequences if left untreated," Anna Windle, a senior vice president at Novo Nordisk, said in a statement Tuesday, per a Bloomberg <a href="https://www.bloomberg.com/news/articles/2025-01-28/novo-s-ozempic-notches-approval-for-kidney-disease-widening-use?sref=TBDibEcD">report</a>.&nbsp;
Ozempic and other diabetes drugs known as GLP-1s have become popular and also well-known for their high cost.&nbsp;
Earlier in January, Novo Nordisk's diabetes and weight loss drugs, Ozempic, Rybelsus, and Wegovy were all added to the U.S. Department of Health and Human Services list of drugs covered under Medicare Part D that<a href="https://www.benzinga.com/25/01/43062779/popular-ozempic-wegovy-selected-for-next-round-of-medicare-drug-price-negotiations"> have been selected</a> for mandated price negotiations in order to reduce <a href="https://www.benzinga.com/general/biotech/24/08/40534249/novo-nordisks-ozempic-might-be-among-2027-medicare-price-negotiation-targets">prescription drug costs</a>.
The negotiations will take place in 2025, with the new prices slated to take effect in 2027.
NVO Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Novo Nordisk shares ended Tuesday's session down 2.65% at $85.19.&nbsp;
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/25/01/43287988/microsoft-q2-preview">Microsoft Q2 Earnings Preview: Street &#8216;Too Optimistic&#8217; On Near-Term AI Returns?&nbsp;</a></li>
</ul>
Photo: Shutterstock

Biotech

Health Care

General

Ozempic Receives FDA Approval To Treat Kidney Disease

Trading Halt: Halt status updated at 5:50:00 PM ET: Quotation Resumption: News and Resumption Times

Finward Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FNWD#NASDAQ">FNWD</a>) reported quarterly earnings of $0.49 per share which beat the analyst consensus estimate of $0.20 by 145 percent. This is a 40 percent increase over earnings of $0.35 per share from the same period last year. The company reported quarterly sales of $16.34 million which beat the analyst consensus estimate of $16.00 million by 2.12 percent. This is a 5.75 percent increase over sales of $15.45 million the same period last year.

Earnings Beats

FNWD

Finward Bancorp Q4 2024 GAAP EPS $0.49 Beats $0.20 Estimate, Sales $16.34M Beat $16.00M Estimate

Compass Point analyst Giuliano Bologna upgrades Affirm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) from Sell to Neutral and raises the price target from $20 to $61.

Upgrades

AFRM

Compass Point Upgrades Affirm Holdings to Neutral, Raises Price Target to $61

The options include a possible sale of the company, business combination, sale of all or part of the Company's assets, licensing of assets, restructuring, or other strategic action.

23andMe Reveals Process To Explore Strategic Alternatives

Compass Point analyst Joe Flynn initiates coverage on Applied Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) with a Buy rating and announces Price Target of $10.

Initiation

APLD

Compass Point Initiates Coverage On Applied Digital with Buy Rating, Announces Price Target of $10

Synaptics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYNA#NASDAQ">SYNA</a>) shares are rising in extended trading Tuesday after the company signed a <a href="https://www.benzinga.com/pressreleases/25/01/g43286953/synaptics-accelerates-edge-ai-strategy-with-new-broadcom-agreement">licensing agreement with Broadcom Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>)</a>.
What Happened: After the market close on Tuesday, Synaptics announced it&#8217;s accelerating its Edge <a href="http://benzinga.com/topic/ai">AI</a> strategy through a definitive licensing agreement with Broadcom.
The agreement includes Wi-Fi&nbsp;8, ultra-wideband (UWB), Wi-Fi 7, advanced Bluetooth and GPS/GNSS products and technology for IoT and the Android ecosystem.
&#8220;Our wireless technology and capabilities are cornerstones of our success in IoT markets,&#8221; said Michael Hurlston, president and CEO of Synaptics. 
&#8220;We are now developing this expertise to enable ecosystems with centralized control and seamless connectivity to a rapidly growing array of Edge AI devices. Our platform history, proven track record, and strategy uniquely position us to integrate Broadcom&#8217;s technology and fully deliver on the potential of IoT connectivity.&#8221;
Check This Out: <a href="https://www.benzinga.com/general/restaurants/25/01/43288533/starbucks-q1-earnings-revenue-beat-eps-beat-memberships-up-1-positive-response-to-turnaround-efforts">Starbucks Q1 Earnings: Revenue Beat, EPS Beat, Memberships Up 1%, &#8216;Positive Response&#8217; To Turnaround Efforts</a>
Synaptics said the deal is expected to add&nbsp;at least $40 million in annualized sales. The company also expects the transaction to be immediately accretive to adjusted earnings per share. 
The all-cash transaction is expected to close on Jan. 30. Financing details were not provided, but Synaptics said it will provide more information on the transaction when it reports <a href="https://www.benzinga.com/calendars/earnings">second-quarter earnings</a> on Feb. 6. 
Analysts currently expect Synaptics to report earnings of 86 cents per share and revenue of $265.14 million for the second quarter, according to <a href="http://pro.benzinga.com">Benzinga Pro</a> estimates.
SYNA Price Action: Synaptics shares were up 5.13% in after-hours, trading at $84.66 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
This illustration was generated using artificial intelligence via Midjourney.

Contracts

After-Hours Center

Tech

AVGO

SYNA

Synaptics Stock Climbs On Broadcom Deal Focused On Edge AI

MGNI

Magnite Says Working With Sky New Zealand To Power Programmatic Advertising On Sports Streaming Platform, Sky Sport Now

Compass Point analyst David Rochester downgrades Synchrony Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYF#NYSE">SYF</a>) from Buy to Neutral and announces $70 price target.

Downgrades

Compass Point Downgrades Synchrony Finl to Neutral, Announces $70 Price Target

Through this contract, Planet joins the Copernicus Contributing Missions, officially contributing commercial satellite data alongside ESA's Sentinel satellite data to the Copernicus services.

Planet Labs Germany GmbH Signs Multi-year Contract With The European Space Agency

CIBC analyst Paul Holden maintains Sun Life Financial (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SLF#TSX">SLF</a>) with a Outperformer and raises the price target from C$96 to C$97.

TSX:SLF

CIBC Maintains Outperformer on Sun Life Financial, Raises Price Target to C$97

It is payable March 17, 2025, to shareholders of record at the close of business on March 3, 2025.

Dividends

Stifel Financial Boosts Quarterly Common Stock Cash Dividend By 10% From $0.42 To $0.46 Per Share

This settlement concludes Aspen's legal action against AMA regarding the unauthorized sale of infringing aerogel insulation materials in Europe.

Legal

ASPN

Aspen Aerogels Reaches Agreement To Resolve Its Patent Dispute With AMA; No Terms Disclosed

CIBC analyst Paul Holden maintains Manulife Financial (TSX:<a class="ticker" href="https://www.benzinga.com/stock/MFC#TSX">MFC</a>) with a Neutral and raises the price target from C$46 to C$47.

TSX:MFC

CIBC Maintains Neutral on Manulife Financial, Raises Price Target to C$47

Primis Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRST#NASDAQ">FRST</a>) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $0.11 by 690.91 percent. This is a 285.71 percent decrease over earnings of $0.35 per share from the same period last year. The company reported quarterly sales of $39.30 million which beat the analyst consensus estimate of $24.78 million by 58.63 percent. This is a 0.17 percent increase over sales of $39.24 million the same period last year.

Earnings Misses

FRST

Primis Finl Q4 Adj EPS $(0.65) May Not Be Comparable to $0.11 Estimate, Sales $39.30M Beat $24.78M Estimate

Flushing Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIC#NASDAQ">FFIC</a>) reported quarterly earnings of $0.14 per share which missed the analyst consensus estimate of $0.22 by 36.36 percent. This is a 44 percent decrease over earnings of $0.25 per share from the same period last year.

FFIC

Flushing Financial Q4 2024 Adj EPS $0.14 Misses $0.22 Estimate

To improve financial condition and liquidity position, it is attempting to raise additional capital and working to implement cost-cutting measures, including additional reductions in operating expenses, negotiating terminations of long-term real estate leases, and attempting to reach a settlement covering all U.S. customers affected by the cyber incident as well as to resolve non-U.S. litigation and ongoing investigations from various governmental agencies arising from the cyber incident.

Guidance

23andMe Notes Continued Concerns Regarding Liquidity, Consideration Of Potential Ways To Address Operational And Financial Challenges

Barclays analyst Christine Cho maintains Sunrun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) with a Equal-Weight and lowers the price target from $18 to $15.

Barclays Maintains Equal-Weight on Sunrun, Lowers Price Target to $15

Three-year targets of 20% revenue CAGR and achievement of cash flow breakeven.

NPCE

NeuroPace Expects FY25 Revenue Of $92M – $96M (Est $91.239M), Gross Margin Of 73% – 75%

Press Releases

FTAI Infrastructure Inc. Announces Timing of Fourth Quarter and Full Year 2023 Earnings and Conference Call

FTAI Infrastructure Inc. Reports Fourth Quarter and Full Year 2023 Results, Declares Dividend of $0.03 per Share of Common Stock

FTAI Infrastructure Inc. Announces Timing of First Quarter 2024 Earnings and Conference Call

FTAI Infrastructure Inc. Reports First Quarter 2024 Results, Declares Dividend of $0.03 per Share of Common Stock

Jefferson Energy, Aramco Trading Americas Execute Agreement for Bi-Directional Flow on Jefferson Southern Star Pipeline; Will Provide Access from Marketlink Pipeline to Jefferson Energy's Beaumont Terminal

FTAI Infrastructure Inc. Announces Timing of Second Quarter 2024 Earnings and Conference Call

FTAI Infrastructure Inc. Reports Second Quarter 2024 Results, Declares Dividend of $0.03 per Share of Common Stock

FTAI Infrastructure Inc. Announces Timing of Third Quarter 2024 Earnings and Conference Call

FTAI Infrastructure Inc. Reports Third Quarter 2024 Results, Declares Dividend of $0.03 per Share of Common Stock

FTAI Infrastructure Inc. Announces Timing of Fourth Quarter and Full Year 2024 Earnings and Conference Call

JMP Securities

Government Trades

FTAI Infrastructure Inc

top performing FIP trades

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga